Identifying Drugs Associated With Parkinson's Disease Risk Using Machine Learning. [PDF]
Pylkkö E +8 more
europepmc +1 more source
Designing novel bisquinoline antimalarials from historical 4-aminoquinolines to combat drug-resistant malaria. [PDF]
Handford MJ +5 more
europepmc +1 more source
<i>In vitro</i> and <i>in vivo</i> studies of dehydroxylated-isoquines and -isotebuquines against trypanosomatids: a preclinical drug candidate for treatment of cutaneous leishmaniasis. [PDF]
Romero AH +9 more
europepmc +1 more source
The Deanes' malarias and the antimalarial drugs in 1939 and the 1940s. [PDF]
Paumgartten FJR +2 more
europepmc +1 more source
Editorial: Quinoline as lead structures for the development of leishmanicidal agents. [PDF]
Romero AH, Benaim G.
europepmc +1 more source
Investigation of the activity of 4-aminoquinolines as cysteine protease inhibitors with application in the treatment of Chagas disease. [PDF]
Sheu-Idrees R +10 more
europepmc +1 more source
Fractional curative killing of pyronaridine or artesunate combinations with tafenoquine, 4-aminoquinolines, or azithromycin in a murine malaria-luciferase model. [PDF]
Lee G, Aneke JS, Sullivan DJ.
europepmc +1 more source
For the eradication of malaria from hyperendemic regions of tropical Africa it is apparent that use may have to be made of antimalarial drugs, administered individually on a census basis, in addition to measures directed against the mosquito. The suppressive activity of existing compounds among individuals having different degrees of immunity is well ...
openaire +1 more source
Moving towards high-dose primaquine or single-dose tafenoquine for Plasmodium vivax treatment in Cambodia: a meeting report from dissemination of results of the EFFORT trial to stakeholders. [PDF]
Dysoley L +52 more
europepmc +1 more source
Amplicon-based DNA sequencing to characterize Duffy antigen polymorphisms and analysis of Duffy blood system and glucose-6-phosphate dehydrogenase deficiency in Mauritania. [PDF]
Fontaine A +5 more
europepmc +1 more source

